Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections

Clinical Microbiology and Infection

Volumn 19, Issue 1, 2013, Pages 62-68

  Kim, S H ^a   Yoon, Y K ^a   Kim, M J ^a   Sohn, J W ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Bacteraemia; Candidaemia; Co infection; Risk factors; Treatment outcome

Indexed keywords

ADULT; AGED; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CANDIDEMIA; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PATHOGEN CLEARANCE; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEPTIC SHOCK;

BACTERIA (MICROORGANISMS); CANDIDA; STAPHYLOCOCCUS;

EID: 84871621449     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03906.x     Document Type: Article

References (31)

1. Peleg AY, Hogan DA, Mylonakis E. Medically important bacterial-fungal interactions. Nat Rev Microbiol 2010; 8: 340-349.
2. Shirtliff ME, Peters BM, Jabra-Rizk MA. Cross-kingdom interactions: Candida albicans and bacteria. FEMS Microbiol Lett 2009; 299: 1-8.
3. Wargo MJ, Hogan DA. Fungal-bacterial interactions: a mixed bag of mingling microbes. Curr Opin Microbiol 2006; 9: 359-364.
4. Klotz SA, Chasin BS, Powell B, Gaur NK, Lipke PN. Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. Diagn Microbiol Infect Dis 2007; 59: 401-406.
5. Hermann C, Hermann J, Munzel U, Ruchel R. Bacterial flora accompanying Candida yeasts in clinical specimens. Mycoses 1999; 42: 619-627.
6. Azoulay E, Timsit JF, Tafflet M et al. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 2006; 129: 110-117.
7. Akagawa G, Abe S, Yamaguchi H. Mortality of Candida albicans-infected mice is facilitated by superinfection of Escherichia coli or administration of its lipopolysaccharide. J Infect Dis 1995; 171: 1539-1544.
8. Carlson E. Effect of strain of Staphylococcus aureus on synergism with Candida albicans resulting in mouse mortality and morbidity. Infect Immun 1983; 42: 285-292.
9. Grillot R, Portmann-Coffin V, Ambroise-Thomas P. Growth inhibition of pathogenic yeasts by Pseudomonas aeruginosa in vitro: clinical implications in blood cultures. Mycoses 1994; 37: 343-347.
10. Kaleli I, Cevahir N, Demir M, Yildirim U, Sahin R. Anticandidal activity of Pseudomonas aeruginosa strains isolated from clinical specimens. Mycoses 2007; 50: 74-78.
11. Peleg AY, Tampakakis E, Fuchs BB, Eliopoulos GM, Moellering RC Jr, Mylonakis E. Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. Proc Natl Acad Sci U S A 2008; 105: 14585-14590.
12. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-322.
13. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in italy. PLoS one 2011; 6: e24198.
14. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut?Clin Infect Dis 2001; 33: 1959-1967.
15. Dyess DL, Garrison RN, Fry DE. Candida sepsis. Implications of polymicrobial blood-borne infection. Arch Surg 1985; 120: 345-348.
16. Bekeris LG, Tworek JA, Walsh MK, Valenstein PN. Trends in blood culture contamination: a College of American Pathologists Q-tracks study of 356 institutions. Arch Pathol Lab Med 2005; 129: 1222-1225.
17. Nace HL, Horn D, Neofytos D. Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007. Diagn Microbiol Infect Dis 2009; 64: 289-294.
18. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
19. Rhee JY, Kwon KT, Ki HK et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009; 31: 146-150.
20. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-710.
21. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
22. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-683.
23. Pulimood S, Ganesan L, Alangaden G, Chandrasekar P. Polymicrobial candidemia. Diagn Microbiol Infect Dis 2002; 44: 353-357.
24. Thorn JL, Gilchrist KB, Sobonya RE, Gaur NK, Lipke PN, Klotz SA. Postmortem candidaemia: marker of disseminated disease. J Clin Pathol 2010; 63: 337-340.
25. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-1128.
26. Hockey LJ, Fujita NK, Gibson TR, Rotrosen D, Montgomerie JZ, Edwards JE Jr. Detection of fungemia obscured by concomitant bacteremia: in vitro and in vivo studies. J Clin Microbiol 1982; 16: 1080-1085.
27. Adam B, Baillie GS, Douglas LJ. Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J Med Microbiol 2002; 51: 344-349.
28. Carlson E. Enhancement by Candida albicans of Staphylococcus aureus, Serratia marcescens, and Streptococcus faecalis in the establishment of infection in mice. Infect Immun 1983; 39: 193-197.
29. Bandara HM, Yau JY, Watt RM, Jin LJ, Samaranayake LP. Pseudomonas aeruginosa inhibits in-vitro Candida biofilm development. BMC Microbiol 2010; 10: 125.
30. Nseir S, Jozefowicz E, Cavestri B et al. Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study. Intensive Care Med 2007; 33: 137-142.
31. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68: 5459-5463.